Already paying cash for a GLP-1? What the Medicare Bridge means for you
Thousands of people on Medicare have been paying out of pocket for Wegovy or Zepbound because Part D wouldn’t cover weight-loss use. If that’s you, the Bridge has one rule written almost specifically for your situation — and it works in your favor: eligibility is judged by your health at the time you started the drug, not where you are today.
The rule that matters most for self-payers
CMS states that eligible beneficiaries must meet the clinical criteria "at the time of GLP-1 therapy initiation" — explicitly including people who began therapy before enrolling in Part D and before the Bridge launched on July 1, 2026. [v2-8] [v2-1]
CMS spells it out with its own example: someone started GLP-1 therapy in September 2024 with a BMI of 37; in July 2026 they seek the Bridge and their BMI is now 34. The prescriber attests based on the initiation-time BMI of 37 — which meets the ≥35 tier — so they can qualify despite the lower current BMI. [v2-8]
In other words: the weight you already lost while self-paying does not disqualify you. [v2-8] If you met the criteria when you started, that is the number your doctor attests to. [v2-8]
What you'd need for the switch
1. Be in an eligible Part D plan. The Bridge requires enrollment in a standalone Part D plan or an MA-PD coordinated care plan (HMO, HMOPOS, local/regional PPO). [v2-10] If you've been fully self-pay and are not in a Part D plan, that enrollment comes first — the initiation-time rule still covers people who started therapy before Part D enrollment. [v2-8]
2. Confirm your indication routes to the Bridge, not Part D. If your GLP-1 relates to type 2 diabetes, moderate-to-severe OSA, or noncirrhotic MASH, CMS routes coverage through your Part D plan instead — those diagnoses make you ineligible for the Bridge even if you meet the clinical criteria. [v2-9]
3. Check the criteria as of your start date. Three tiers: BMI ≥35; BMI ≥30 plus a listed condition (HFpEF, uncontrolled hypertension on two medications, CKD 3a+); or BMI ≥27 plus a listed condition (ADA-defined pre-diabetes, prior heart attack, prior stroke, symptomatic PAD) — measured at therapy initiation. [v2-7] [v2-8] Full tier-by-tier detail is in the eligibility guide.
4. Check your formulation. Foundayo and Wegovy are covered in all formulations, but Zepbound is covered only as the KwikPen — single-dose vials and single-dose pens are not available through the Bridge. [v2-5] [v2-6] Many cash-pay programs ship exactly those vials, so this is the switch-trap to watch: if you're on Zepbound vials, ask your prescriber about the KwikPen. [v2-6]
5. Your doctor submits the PA. You don't apply directly — your prescriber submits a prior authorization (electronically or by fax) along with the prescription, and attests to the clinical criteria in it. [v2-11] [v2-7]
What switching gets you — and what it doesn't
Once approved, eligible beneficiaries have a $50 copay for the covered drug. [v2-3] Note the CMS page attaches no frequency word to the $50, so don't assume any particular frequency — confirm how it applies to your fills via the official page or 1-800-MEDICARE. [v2-3] [v2-12] The Part D deductible does not apply, the copay does not count toward TrOOP, and there is no LIS subsidy on it. [v2-3]
Also keep the horizon in view: the Bridge is a time-limited demonstration running through December 31, 2027. [v2-1] What happens after that is covered in our after-2027 guide.
Paperwork tip for the doctor conversation
Since the attestation is about your status at therapy initiation [v2-8], records from when you started — the original prescription date, weight/BMI notes from that visit, any diagnoses that fit the criteria tiers — are what your prescriber needs at hand. If you started at another practice or via a telehealth service, request those records now so your current prescriber can attest accurately. (General preparation advice, not a CMS requirement — the required submission itself is the prescriber's PA plus prescription. [v2-11])
This page summarizes public CMS guidance as of July 2026 and is general information, not medical or insurance advice. Eligibility is attested by your prescriber in the prior authorization, and program details are set by CMS and may change. Always confirm current rules on the official CMS Medicare GLP-1 Bridge page and at Medicare.gov/glp1bridge. [v2-12]
Frequently asked questions
I've lost 30 pounds self-paying and my BMI is below the thresholds now. Am I locked out?
The criteria are measured at therapy initiation — CMS's own example qualifies a person who started at BMI 37 and applied at BMI 34. [v2-8] Talk to your prescriber about what your records show for your start date. [v2-8]
I buy Zepbound vials directly from the manufacturer. Can I just move that to the Bridge?
Not in that formulation — only the Zepbound KwikPen is covered; single-dose vials and pens are not. [v2-6] Ask your prescriber whether the KwikPen works for you. [v2-6]
I'm not enrolled in Part D. Can I still use the Bridge?
Enrollment in an eligible Part D plan type is required. [v2-10] The initiation-time rule explicitly covers people who started therapy before Part D enrollment, so prior self-pay history doesn't bar you once enrolled. [v2-8]
Does what I already spent out of pocket count toward anything?
The CMS pages we cite don't address retroactive credit for past cash payments — check with 1-800-MEDICARE or the official CMS page. [v2-12]
GLP-1 coverage denied or prior auth stuck? Appeal it free
IntelClaim’s free diagnosis tells you what you’re holding, whether it’s worth fighting, and which path fits — then helps you build the appeal or PA request. Purpose-built, self-help, you stay in control.
IntelClaim is a self-help tool — not legal, medical, or insurance advice — and does not guarantee any particular outcome. Information on this site is general and may not reflect the rules of your specific plan or state. Always read your own denial letter, plan documents, and the deadlines that apply to you, and consider professional advice for your situation. No PHI is collected on this marketing site.